METHOD DEVELOPMENT AND ITS VALIDATION FOR QUANTITATIVE DETERMINATION OF BOSENTAN IN TABLET DOSAGE FORM BY RP-HPLC
Abstract
Objectives of this research work were development and validation of HPLC methods of analysis for Bosentan in tablet dosage form from single components as per the current ICH & USP guidelines. HPLC methods also validated for the marketed Bosentan from single components. This developed procedure applied for regular analysis of these medicaments in pharmaceutical industry The major scope of research is development of simple, accurate, reproducible & fast cost effective methods for new cefalosporins. The methods are validated with recovery studies using bulk drug of 80%, 120% & 40%. Specific method is confirmed by checkingdinterference of expients & assay method. The interday & intraday assay are also performed for checking robustness of the system. The minimum detection limit is checked by using formula LOD = 3.3 sigma (St&nd deviation) / Slop, where σ indicate st&ard deviation & S denotes slop of the regression straight line. The wuantification limit is detrmined by using LOQ = 10 σ d(St&. dev.)/ S that is minimum concentration of drug can be quantified. Linearity is found in the limit of Beer’s law, straight line was constructed within the given range of the conc. of the drugs. So can develop & validate a new, reproducible, correct, & easy, less time consuming, cheap & ecofriendly method for daily analysis of drug in our general life.
Keywords: Bosentan, RP HPLC, method development and validation.
DOI
https://doi.org/10.22270/jddt.v7i2.1409References
Weber C, Banken L, Birnboeck H, Nave S, Schulz R. The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects. Br J Clin Pharmacol. 1999, 47, 701-706.
Weber C, Gasser R, Hopfgartner G. Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metab Dispos. 1999, 27, 810-815.
Weber C, Schmitt R, Birnboeck H, Hopfgartner G. Pharmaco kinetics and pharmaco dynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther. 1996, 60, 124-137.
Weber C, Schmitt R, Birnboeck H, Hopfgartner G, Eggers H. Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. J Clin Pharmacol. 1999, 39, 703-714.
O' Neil MJ, editor. The Merck Index: An Encyclopedia of Chemicals, Drug and Biologicals. 2006.
Dell D, Lausecker B, Hopfgartner G, Giersbergen P L M V and Dingemanse J. Evolving bio analytical methods for the cardiovascular drug bosentan. Chromatographia. 2002, 55, Supplement 1, S115-119.
Chavanpatil M D, Rajeshkumar N V, Gulati A. Determination of endothelin antagonist BMS182874 in plasma by high-performance liquid chromatography. Die Pharmazie. 2006, 61, 525-527.
Karnaker Reddy T, Younus Md, Ravindra Reddy.Y, Ashwini kumar G, Sravan S. RP-HPLC method development and validation of bosentan drug present in tablets. Int J Pharm Tech. 2010, 2, 577-587.
Ashwini G, Aravindsai N, Karnaker Reddy T, Kumar A. Estimation of Febuxostat drug present in formulation by RP-HPLC. Journal of Pharmacy Research, 2012; 5(2): 1224- 1227
Agarwal A, Tiwari S, Nagariya K, Method development and its validation for quantitative simultaneous determination of latanoprost, timolol and benzalkonium chloride in ophthalmic solution by RP-HPLC, Journal of Drug Delivery & Therapeutics; 2013; 3(2):26-30
Shah J, Parmar K, Development & validation of HPLC method for analysis of some an-tihypertensive agents in their pharmaceutical dosage forms, Journal of Drug Delivery & Therapeutics; 2014; 4(2):12-15
Bhowmick M, Bhowmick P, Sengodan T, Thangavel S, Development and validation of bioanalytical RP HPLC method for the estimation of metoprolol tartrate in rabbit plasma after transdermal and oral administration: application in pharmacokinetic studies, Journal of Drug Delivery & Therapeutics; 2015; 5(4):43-53
Published
Abstract Display: 684 
PDF Downloads: 740 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.